Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $28.8 million, representing a 41% increase year-over-year, while total revenue for fiscal 2025 was $88.5 million, a 24% increase [13] - Lung diagnostics revenue for Q4 2025 was $25.1 million, up 46% year-over-year, and $79.2 million for fiscal 2025, a 22% increase [13] - Adjusted EBITDA for Q4 2025 was positive at $530,000, marking the company's first positive adjusted EBITDA quarter, an improvement of 113% over Q4 2024 [17] - Gross margin for Q4 2025 was 83%, a 400 basis point improvement, while the fiscal 2025 gross margin was 81%, a 300 basis point improvement [15] Business Line Data and Key Metrics Changes - Test volumes for lung diagnostics were 18,000 in Q4 2025, a 23% increase, and 62,600 for fiscal 2025, a 15% increase [13] - Average revenue per test increased due to advancements in reimbursement and improved claims collection, contributing to the overall revenue growth [15][17] - Development services revenue for Q4 2025 was $3.6 million, a 12% increase, and $9.3 million for fiscal 2025, a 41% increase [14] Market Data and Key Metrics Changes - Volumes from primary care accounted for 12% of total Nodify tests in Q4 2025, growing 67% year-over-year, while volumes from pulmonology grew 26% [6] - The company expanded its sales strategy into primary care, accessing the remaining 50% of the nodule market managed by primary care physicians [6] Company Strategy and Development Direction - The company is focused on three main goals for 2025 and 2026: growing top-line revenue, improving organizational effectiveness, and advancing its product pipeline [3] - The strategy includes a three-tiered approach to lung nodule management, enhancing the value of Nodify Lung testing [4][6] - Partnerships with Thermo Fisher Scientific and Bio-Rad Laboratories were announced to develop and validate tests, showcasing the company's capabilities [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to execute against long-term opportunities, emphasizing operational discipline and capital efficiency [21][22] - Guidance for 2026 anticipates annual revenue between $106 million and $112 million, representing a 23% growth over 2025 [19] Other Important Information - The company ended Q4 2025 with $19.0 million in unrestricted cash, a 14% increase over the previous quarter, and raised an additional $14.7 million in at-the-market proceeds [18] - The company plans to add approximately six sales representatives per quarter in 2026 to enhance market penetration [16] Q&A Session Summary Question: Expected revenue and volume step down in Q1 - Management acknowledged weather disruptions and noted that Q1 typically sees a step down in average selling price and volume, consistent with historical seasonality [26][27] Question: Pipeline developments and future tests - Management indicated that no new tests would be commercialized within the next 12 months, focusing on profitability and reimbursement timing [30] Question: Primary care sales rep productivity - The primary care focus has grown to 12% of total Nodify orders, with expectations for continued growth as the sales team matures [33] Question: Cash position and need for additional cushion - Management expressed confidence in the cash position, strengthened by operational improvements and additional cash raised [41] Question: Evidence of shifting stage in lung cancer diagnosis - Management encouraged physicians to publish data on the positive impact of Nodify testing, emphasizing the importance of awareness and compliance [46] Question: Updates on clinical studies and data readouts - Management plans to continue submitting data from the CLARIFY study and indicated that ALTITUDE data will not be available until 2027 [52]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $28.8 million, representing a 41% increase year-over-year, while total revenue for fiscal 2025 was $88.5 million, up 24% from the previous year [12] - Lung diagnostics revenue reached $25.1 million in Q4 2025, a 46% increase year-over-year, and $79.2 million for the fiscal year, a 22% increase [12] - Adjusted EBITDA for Q4 2025 was positive at $530,000, marking the company's first positive Adjusted EBITDA quarter, an improvement of 113% over Q4 2024 [17] - Gross margin improved to 83% in Q4 2025, a 400 basis point increase, and 81% for the fiscal year, a 300 basis point improvement [15] Business Line Data and Key Metrics Changes - Test volumes for lung diagnostics were 18,000 in Q4 2025, a 23% increase, and 62,600 for the fiscal year, a 15% increase [12] - Average revenue per test increased due to advancements in reimbursement and improved claims collection, contributing to the overall revenue growth [12][15] - Development services revenue was $3.6 million for Q4 2025, a 12% increase, and $9.3 million for the fiscal year, a 41% increase [13] Market Data and Key Metrics Changes - Volumes from primary care accounted for 12% of total Nodify tests in Q4 2025, growing 67% year-over-year, while volumes from pulmonology grew 26% [5] - The company expanded its sales strategy into primary care, accessing an additional 50% of the available nodule market [5] Company Strategy and Development Direction - The company is focused on three main goals: growing top-line revenue, improving organizational effectiveness, and advancing its pipeline for future growth [3] - A three-tiered commercial strategy has been implemented to enhance lung nodule management through the use of Nodify Lung testing [4] - Partnerships with Thermo Fisher Scientific and Bio-Rad Laboratories have been established to develop and validate tests, showcasing the company's capabilities [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to execute against significant long-term opportunities, emphasizing operational discipline and capital efficiency [21] - Guidance for 2026 anticipates annual revenue between $106 million and $112 million, representing a 23% growth over 2025 [19] - The company acknowledged potential challenges from weather events and historical seasonality in Q1, which have been factored into the guidance [19] Other Important Information - The company ended Q4 2025 with $19.0 million in unrestricted cash, a 14% increase over the previous quarter, and raised an additional $14.7 million in at-the-market proceeds [18] - The company plans to add approximately 6 sales representatives per quarter in 2026 to enhance market penetration [16] Q&A Session Summary Question: Expected revenue and volume step down in Q1 - Management acknowledged weather disruptions and noted that Q1 typically sees a step down in average selling price and volume, consistent with historical seasonality [24][26] Question: Pipeline developments and future tests - Management indicated that no new tests are planned for commercialization within the next 12 months, focusing instead on reimbursement timing and appropriate studies [28] Question: Performance of primary care sales representatives - Primary care sales representatives accounted for 12% of total Nodify orders, with expectations for continued growth as the sales team matures [32] Question: Cash position and need for additional cushion - Management expressed confidence in the current cash position, highlighting operational improvements and the strength of the balance sheet [40] Question: Evidence of shifting stage in lung cancer diagnosis - Management encouraged physicians to publish data on the positive impact of Nodify testing, emphasizing the importance of awareness and compliance [46] Question: Updates on clinical studies and data readouts - Management confirmed ongoing efforts to publish real-world data from the CLARIFY study and noted that data from the ALTITUDE study will not be available until 2027 [52][53]

Core Insights - The article discusses the latest research published in the journal "Clinical Medicine Insights: Oncology," focusing on cancer research and treatment, including various aspects such as molecular biology, genetics, and clinical interventions [4]. Group 1: Journal Overview - "Clinical Medicine Insights: Oncology" is an international, peer-reviewed open access journal that publishes articles on all aspects of cancer research and treatment [2]. - The journal currently has an impact factor (IF) of 1.9, with a predicted increase to 2.5 in the upcoming update [3]. Group 2: Recent Research Highlights - A recent clinical study titled "Effectiveness and Safety of Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma" included 48 patients with unresectable hepatocellular carcinoma (uHCC), showing an objective response rate (ORR) of 39.6% and a disease control rate (DCR) of 70.8% based on RECIST 1.1 criteria [6][8]. - The study found that 75% of patients experienced adverse events, with the most common being thrombocytopenia (27.1%), lymphocytopenia (25%), and liver function abnormalities (14.6%) [8][9]. Group 3: AI in Colorectal Cancer Treatment - A highly cited paper discusses the applications of artificial intelligence (AI) in colorectal cancer treatment, highlighting its potential to predict treatment outcomes and guide personalized treatment strategies [11][14]. - The review included 49 relevant papers, indicating that AI shows promising results in treatment strategy selection and prognosis assessment for colorectal cancer patients [14]. Group 4: Multi-Omics Approaches in Cancer Research - Another notable paper emphasizes the integration of multi-omics methodologies, which combine genomics, transcriptomics, proteomics, and metabolomics, to enhance understanding of cancer biology and improve personalized treatment [16][18]. - The advancements in proteomics and mass spectrometry are expected to improve the accuracy of predicting treatment responses, thereby benefiting drug development and patient outcomes [18].

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was $21.8 million, representing a 20% increase year-over-year [17] - Gross margin improved by 400 basis points to 81% compared to 77% in Q3 2024 [19] - Adjusted EBITDA loss improved by 18% year-over-year to a loss of $4.6 million [21] Business Line Data and Key Metrics Changes - Lung diagnostic testing revenue was $19.8 million from approximately 15,700 tests, a 16% increase in revenue and 13% growth in test volumes compared to Q3 2024 [18] - Development services revenue grew 97% year-over-year to $1.9 million, with $12.9 million under contract, marking a 16% increase [14][19] Market Data and Key Metrics Changes - The company expanded its access to the lung nodule market, increasing the percentage of Nodify tests ordered from primary care from 4% to 11% in September 2025 [7] - Digital test ordering capabilities increased by 43% over the previous year [10] Company Strategy and Development Direction - The company is focused on three main goals: growing top-line revenue, improving operational effectiveness, and advancing its product pipeline [4] - A three-tiered commercial strategy has been implemented to enhance lung nodule management and increase growth potential [5] - The company is leveraging partnerships with Bio-Rad Laboratories and Thermo Fisher Scientific to expand its product development pipeline [15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving adjusted EBITDA positivity in Q4 2025, supported by strong revenue growth and improved gross margins [22][37] - The company is increasing its revenue guidance for 2025 to a range of $84-$86 million based on current momentum [17] Other Important Information - The company presented interim data from the Clarify study at the CHEST annual meeting, reinforcing the clinical utility of Nodify testing [11][12] - The company is actively working to resolve administrative barriers with Medicare Advantage plans, which contributed to revenue growth [18] Q&A Session Summary Question: Can you discuss the signals that your primary care expansion is working? - Management highlighted that initial proof points come from pulmonologists introducing the company to their referral networks, leading to increased adoption and earlier diagnosis [25][26] Question: What can investors expect regarding product portfolio expansion into 2026? - Management indicated that an R&D event will provide updates on ongoing efforts and pipeline developments, emphasizing the importance of partnerships [28][29] Question: What is the ramp-up plan for the new sales reps and expected productivity? - Management noted a consistent ramp-up in sales rep productivity, aiming for $1 million per sales rep at full productivity [31][32] Question: How confident is the company in achieving adjusted EBITDA positivity in Q4? - Management expressed strong confidence in reaching adjusted EBITDA positivity based on Q3 performance and momentum into Q4 [36][37]

Financial Data and Key Metrics Changes - Total revenue for Q2 2025 was $20 million, representing a 12% increase year over year [18] - Gross margin improved to 80%, up 150 basis points from 78.4% in Q2 2024 [19] - Net loss for Q2 2025 was $11.5 million, an increase of 6% year over year [20] - Adjusted EBITDA loss was $7.2 million, which is a 29% increase year over year [20] - Cash used from operations improved by 23% to $6.6 million compared to $8.6 million in Q2 2024 [20] Business Line Data and Key Metrics Changes - Lung diagnostic testing revenue was $17.9 million from approximately 15,100 tests, compared to $16.5 million from approximately 13,900 tests in Q2 2024, representing 9% growth in test volumes and 8% growth in revenue [18] - Development services revenue grew by 53% year over year to $2.1 million [18][16] Market Data and Key Metrics Changes - The company ended Q2 2025 with $12.5 million under contract for development services, marking a 54% increase year over year and an all-time high [18][16] - The average number of sales representatives in the field was 74, with plans to increase to 83-87 in Q3 and 93-97 in Q4 [10][21] Company Strategy and Development Direction - The company aims to grow top-line revenue, improve operational effectiveness, and achieve positive adjusted EBITDA by Q4 2025 [5] - A territory-based sales strategy was implemented to engage pulmonologists and their referral networks, addressing nearly 50% of patients with lung nodules managed by primary care [7][6] - The company is focused on expanding its clinical evidence base and pipeline, with multiple presentations at key conferences [12][13][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the primary care strategy, noting that feedback from pulmonologists supports the approach [30] - The company anticipates continued growth in the development services segment, particularly in Q4 due to pharmaceutical budget cycles [45] - Management remains optimistic about achieving adjusted EBITDA positivity in Q4 2025, driven primarily by revenue growth [21][40] Other Important Information - The company has made significant progress in clinical studies, including the ALPITUDE study, which has reached patient enrollment requirements [23][12] - The company was recognized as a top workplace for the second consecutive year, reflecting its strong culture and team [24] Q&A Session Summary Question: Can you unpack the primary care opportunity and your confidence in the strategy? - Management indicated that confidence has increased due to broader experiences and consistent feedback from pulmonologists [30][29] Question: What trends are seen in electronic ordering utilization? - Management noted that electronic ordering has improved compliance and reduced test cancellations, enhancing efficiency [36][35] Question: How will the company bridge to EBITDA positivity in Q4? - The primary driver will be revenue growth from an increased number of sales representatives, with no major cost-cutting measures planned [40][42] Question: What is the outlook for development services revenue? - Management expects an uptick in Q4 due to the typical cadence of pharmaceutical companies' budgeting [45] Question: What is the growth outlook for primary care orders? - Management stated that while primary care orders have increased significantly, forecasting the exact mix with pulmonology is challenging [60][59] Question: What are the capital needs over the next year and a half? - Management is focused on achieving both adjusted EBITDA and cash flow breakeven with existing plans [71] Question: How confident is the company in maintaining $1 million per rep productivity? - Management expressed confidence based on pilot program results, indicating potential for higher productivity in some territories [73][75]

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $18 million, representing a 21% increase year over year [22] - Lung diagnostic testing revenue was $16.3 million, reflecting an 18% growth, with test volumes increasing by 16% [22][24] - Gross margin improved to 79.4%, up from 78.6% in Q1 2024 [23] - Net loss for Q1 2025 was $11.1 million, an 18% improvement year over year [24] - Adjusted EBITDA loss was $6.2 million, an 11% improvement year over year [24] Business Line Data and Key Metrics Changes - Lung diagnostics revenue grew by 18%, marking the sixteenth consecutive quarter of over 15% year-over-year growth [5] - Development services revenue reached $1.7 million, a 61% increase compared to Q1 2024 [20] - The pipeline for development services ended Q1 with $10.9 million under contract, a 21% increase year over year [23] Market Data and Key Metrics Changes - The company is focusing on expanding its presence in the primary care market, which is expected to enhance patient access to lung diagnostics [9][12] - Digital test ordering increased by 58% over the last year, with customer retention for digital ordering being 40% higher than for non-digital ordering [8] Company Strategy and Development Direction - The company aims to achieve positive adjusted EBITDA by Q4 2025 while focusing on revenue growth and operational efficiencies [4][26] - A shift to a territory-based sales approach has been implemented to enhance market penetration in both pulmonology and primary care [9][11] - The company is exploring the integration of AI and radiomics into its diagnostic offerings to improve clinical workflows [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving adjusted EBITDA positivity in Q4 2025 despite current challenges in the sales force expansion [24][44] - The company is optimistic about the growth potential in the primary care market, supported by positive feedback from pulmonologists [42][61] - Management acknowledged the need for careful monitoring of expenses while ramping up the sales team to meet growth targets [78] Other Important Information - The company has been recognized as a top workplace for the second consecutive year in 2025, highlighting its strong team culture [28] - The company plans to hold an R&D day in the fall to provide further insights into its pipeline and progress [20] Q&A Session Summary Question: Can you elaborate on the sales force changes and hiring challenges? - Management noted that the shift to primary care required a different hiring profile, which took longer than anticipated to finalize [32][34] Question: What is the outlook for Q2 and the rest of the year? - Management expects to have 70 to 75 sales reps in Q2, with plans to increase to 85 in Q3 and 95 in Q4 [39] Question: How are primary care physicians responding to the technology? - Early feedback indicates that primary care physicians are aware of the patient population and are interested in utilizing the diagnostic tests [41][61] Question: What is the impact of the $10 million loan on capital needs? - The additional capital provides more flexibility and confidence in achieving breakeven while supporting commercial expansion and pipeline activities [44][45] Question: How does the sales force configuration affect territory management? - Each territory will have a pulmonology sales consultant, with associate sales consultants supporting them based on specific needs and test volumes [92][93]